PHARMACODYNAMIC AND PHARMACOKINETIC STUDY OF VERINURAD (RDEA3170) IN ADULT MALE SUBJECTS WITH MILD, MODERATE, AND SEVERE RENAL IMPAIRMENT: A PHASE 1, OPEN-LABEL STUDY

被引：0
|
作者：
Smith, W. B. [1 ]
Hall, J. [2 ]
Berg, J. K. [3 ]
Kazimir, M. [3 ]
Yamamoto, A. [2 ]
Walker, S. [4 ]
Lee, C. [2 ]
Marbury, T. C. [5 ]
机构：
[1] Volunteer Res Grp, Knoxville, TN USA
[2] Ardea Biosci Inc, San Diego, CA USA
[3] DaVita Clin Res, Minneapolis, MN USA
[4] Astrazeneca, Gaithersburg, MD USA
[5] Orlando Clin Res Ctr, Orlando, FL USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.5327
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0433
引用
收藏
页码：371 / 371
页数：1
相关论文
共 50 条
  • [31] Pharmacokinetics, safety, and tolerability of etrasimod (APD334) in subjects with mild, moderate, or severe hepatic impairment: a single-dose, open-label, parallel-group study
    Lee, C.
    Tang, Y.
    Schroeder, C.
    Zhang, J.
    Nguyen-Cleary, T.
    Mullin, S.
    Ma, M.
    Lyon, N.
    Grundy, J.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S321 - S322
  • [32] An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema
    Weatherhead, S. C.
    Wahie, S.
    Reynolds, N. J.
    Meggitt, S. J.
    BRITISH JOURNAL OF DERMATOLOGY, 2007, 156 (02) : 346 - 351
  • [33] Apremilast for the Treatment of Mild-to-Moderate Hidradenitis Suppurativa in a Prospective, Open-Label, Phase 2 Study
    Kerdel, Franz R.
    Azevedo, Fabio A.
    Kerdel, Christina
    Don, Frank A.
    Fabbrocini, Gabriella
    Kerdel, Francisco A.
    JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (02) : 170 - 176
  • [34] A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment
    Bola Tayo
    Lesley Taylor
    Farhad Sahebkar
    Gilmour Morrison
    Clinical Pharmacokinetics, 2020, 59 : 747 - 755
  • [35] A PHASE 1 STUDY OF THE PHARMACOKIN ETICS OF ADAGRASIB IN SUBJECTS WITH MILD, MODERATE, OR SEVERE HEPATIC IMPAIRMENT COMPARED TO SUBJECTS WITH NORMAL HEPATIC FUNCTION
    Cilliers, C.
    McCloskey, P.
    Morin, J.
    Tran, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S113 - S114
  • [36] Randomized, open-label, two-period crossover comparison of the pharmacokinetic and pharmacodynamic properties of two amlodipine formulations in healthy adult male Korean subjects
    Park, JY
    Kim, KA
    Lee, GS
    Park, PW
    Kim, SL
    Lee, YS
    Lee, YW
    Shin, EK
    CLINICAL THERAPEUTICS, 2004, 26 (05) : 715 - 723
  • [37] A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment
    Tayo, Bola
    Taylor, Lesley
    Sahebkar, Farhad
    Morrison, Gilmour
    CLINICAL PHARMACOKINETICS, 2020, 59 (06) : 747 - 755
  • [38] A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairment
    Ou, Ying C.
    Preston, Richard A.
    Marbury, Thomas C.
    Tang, Zhiyu
    Novotny, William
    Tawashi, Manal
    Li, Ta-Kai
    Sahasranaman, Srikumar
    LEUKEMIA & LYMPHOMA, 2020, 61 (06) : 1355 - 1363
  • [39] Effects of Mild to Severe Hepatic Impairment on the Pharmacokinetics of Sonidegib: A Multicenter, Open-Label, Parallel-Group Study
    Horsmans, Yves
    Zhou, Jocelyn
    Liudmila, Mateva
    Golor, George
    Shibolet, Oren
    Quinlan, Michelle
    Emotte, Corinne
    Boss, Hildegard
    Castro, Henry
    Sellami, Dalila
    Preston, Richard A.
    CLINICAL PHARMACOKINETICS, 2018, 57 (03) : 345 - 354
  • [40] An Open-Label, Phase 1 Study to Assess the Effects of Hepatic Impairment on Pomalidomide Pharmacokinetics
    Li, Yan
    Wang, Xiaomin
    Liu, Liangang
    Zhang, Chengyue
    Gomez, Diana
    Reyes, Josephine
    Palmisano, Maria
    Zhou, Simon
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (03): : 346 - 354
12345